ArticleDigestive diseases and sciences2025
Adrenal Dysfunction in Outpatients with Decompensated Cirrhosis: Impairment in the Hypothalamic-Pituitary-Adrenal Axis.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liver cirrhosis is associated with altered glucocorticoid metabolism related to disease severity.Journal of internal medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
aimsThe pathogenesis of adrenal dysfunction (AD) in cirrhosis is incompletely understood. We aimed to evaluate potential effects of cirrhosis on hypothalamic-pituitary-adrenal axis (HPA) functionality in stable outpatients with decompensated disease.
methodsOutpatients with decompensated cirrhosis were prospectively recruited at a transplant center. Biomarkers reflective of HPA activity, glucocorticoid synthesis, cholesterol metabolism, systemic neurohormonal activity, and the immune system were measured prior to administration of a standard-dose adrenocorticotrophic hormone (ACTH) stimulation test. Adrenal dysfunction was defined as an increase in serum total cortisol level (delta TC) of < 9 µg/dL. Patients were followed for up to 12 months for assessment of clinical outcomes including portal hypertension-related decompensation, hospitalization, liver transplant, and death.
resultsSeventy-six participants were enrolled (AD 33%, normal adrenal function 67%). Median ACTH levels were similar between groups (P = 0.581). The product ratio of the cortisol precursor 17-hydroxyprogesterone to 11-deoxycortisol (11-DOC) was lower in the AD group (0.9 vs. 1.3, P = 0.036), whereas the 11-DOC:cortisol ratio was similar between groups (5.9 vs. 5.0, P = 0.522). Of the 13 measured serum cytokines, only median levels of IL-6 were significantly higher in the AD group (14.71 vs. 8.99 pg/mL, P = 0.024). There were no differences in clinical outcomes between groups.
conclusionsInappropriately low ACTH secretion and alterations in adrenal steroidogenesis are associated with an abnormal response to ACTH stimulation testing in outpatients with decompensated cirrhosis. These findings suggest multilevel HPA axis dysfunction and support the theory that AD represents cirrhosis-induced extrahepatic organ failure. The presence of AD may not be associated with worse liver-related outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.